Regulation - Anti-virals, Cardio-vascular

Filter

Popular Filters

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency

11-03-2013

Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

Novartis makes Tekturna label change, updates on Gilenya and stops alisporivir trial

20-04-2012

In a day of mixed news for the Swiss drug major, Novartis (NOVN: VX) said yesterday that it has updated…

alisporivirAnti-viralsCardio-vascularGilenyaNeurologicalNovartisPharmaceuticalRegulationResearchTekturna

EMA recommends new Rxing info on Victrelis and warnings for aliskiren

20-02-2012

The European Medicines Agency has recommended updating the prescribing information for US drug giant…

Aliskiren TabletsAnti-viralsCardio-vascularEuropeMerck & CoNovartisPharmaceuticalRasilezRegulationTekturnaVictrelis

European Commission OKs Novartis’ Rasitrio and new label for Bristol-Myers’ Reyataz

28-11-2011

Following a positive advisory recommendation in September, the European Commission has now approved Swiss…

Anti-viralsBristol-Myers SquibbCardio-vascularEuropeNovartisPharmaceuticalRasitrioRegulationReyataz

Back to top